[Care pathway for the diagnosis and management of patients with hypertrophic phenotype in the Marche Region: the experience of the Marche Cardiomyopathies Network].
F, V., C, L., F, T., A, R., D, C., R, O., K, M., M, F., E, F., & A, L. (2026). [Care pathway for the diagnosis and management of patients with hypertrophic phenotype in the Marche Region: the experience of the Marche Cardiomyopathies Network].. Giornale italiano di cardiologia (2006). https://doi.org/10.1714/4755.47723
F V, C L, F T, A R, D C, R O, et al. [Care pathway for the diagnosis and management of patients with hypertrophic phenotype in the Marche Region: the experience of the Marche Cardiomyopathies Network].. Giornale italiano di cardiologia (2006). 2026; doi: 10.1714/4755.47723
F V, C L, F T, et al. [Care pathway for the diagnosis and management of patients with hypertrophic phenotype in the Marche Region: the experience of the Marche Cardiomyopathies Network].[J]. Giornale italiano di cardiologia (2006). 2026. DOI: 10.1714/4755.47723.
@article{f2026,
author = {Vagnarelli F and Lofiego C and Terzi F and Romandini A and Contadini D and Olivieri R and Maurizi K and Flori M and Falchetti E and Lanari A},
title = {[Care pathway for the diagnosis and management of patients with hypertrophic phenotype in the Marche Region: the experience of the Marche Cardiomyopathies Network].},
journal = {Giornale italiano di cardiologia (2006)},
year = {2026},
doi = {10.1714/4755.47723},
note = {PMID: 42643134},
}
TY - JOUR AU - Vagnarelli F AU - Lofiego C AU - Terzi F AU - Romandini A AU - Contadini D AU - Olivieri R AU - Maurizi K AU - Flori M AU - Falchetti E AU - Lanari A TI - [Care pathway for the diagnosis and management of patients with hypertrophic phenotype in the Marche Region: the experience of the Marche Cardiomyopathies Network]. T2 - Giornale italiano di cardiologia (2006) PY - 2026 DO - 10.1714/4755.47723 AN - PMID:42643134 ER -
BACKGROUND: The aim of this study was to describe the clinical care pathway and results of the first 6 years of activity of the Marche Cardiomyopathy Network (MCN) dedicated to cardiomyopathies with a hypertrophic phenotype. METHODS: The analysis was based on data from the registry of the regional referral center and on a survey conducted in 2025 within the MCN. RESULTS: Between 2019 and 2025, 552 patients with cardiomyopathy with a hypertrophic phenotype were evaluated at the referral center, with a progressive increase in case volume (from 50 to 552 patients). Cardiac amyloidosis (CA) accounted for 51% of cases, followed by sarcomeric hypertrophic cardiomyopathy (45%) and Anderson-Fabry disease (4%). Among the hereditary forms of CA (Ile68Leu as the most frequent mutation, 50% of cases), the prevalence was 12 per million inhabitants. In peripheral centers, the number of patients in follow-up increased by 209% compared with 2021 (from 211 to 441), with a predominance of CA (67%). Dedicated outpatient clinics were available in 54% of centers, and 85% of them had cardiologists with specific expertise. CONCLUSIONS: The MCN has contributed to increased diagnostic rates, wider dissemination of expertise, and improved access to therapies, highlighting the key role of clinical networks in the management of complex cardiomyopathies.